CellCAN and CCRM partner to launch CATTI – New Institute will tackle gaps in training Canada’s GMP workforce
The fast growth of cell and gene therapies has made it difficult for the global industry to keep up with talent requirements. The volume of clinical trials around the world – approximately 1,200 at this time – puts pressure on manufacturers to scale-up the production of cells and viral vectors. CellCAN, a knowledge mobilization network in cell and gene therapies (CGTs), and CCRM, a leader in developing and commercializing regenerative medicine-based technologies and CGTs, are responding to that challenge by launching the Canadian Advanced Therapies Training Institute (CATTI).